Pre-made Porgaviximab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Porgaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Porgaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody |
|---|---|
| INN Name | Porgaviximab |
| Target | Zaire Ebolavirus GP |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 5kel:HL:PT:QU |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Mapp Biopharmaceutical,Public Health Agency of Canada,National Institute of Allergy and Infectious Diseases |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Ebola virus infections |
| Development Tech | Zmapp Technology |
| Previous Name | NA |
| Gm Offical Target Name | Zaire Ebolavirus GP |
| Package |
